Glioma susceptibility 1: genes and variants
Explore variant evidence for Glioma susceptibility 1 across 4 analyzed proteins (PTEN, TP53, BRCA2, ERBB2). Linked ClinVar records include 12 pathogenic or likely pathogenic variants, 52 variants of uncertain significance and 13 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Glioma susceptibility 1
PTEN: Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
A lipid and protein phosphatase that removes phosphate groups from signaling molecules, especially PIP3. By opposing the PI3K-AKT pathway, it limits cell growth and survival signals, and PTEN variants are associated with Cowden syndrome and multiple cancers.
5 ClinVar pathogenic / likely pathogenic and 29 uncertain variants in PTEN have source records linked to Glioma susceptibility 1. Association strength is not clinical gene validity.
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
5 ClinVar pathogenic / likely pathogenic and 5 uncertain variants in TP53 have source records linked to Glioma susceptibility 1. Association strength is not clinical gene validity.
BRCA2: Breast cancer type 2 susceptibility protein
It loads RAD51 onto damaged DNA to enable homologous recombination and also protects stressed replication forks from degradation. Germline loss-of-function variants strongly predispose to breast, ovarian, prostate, pancreatic, and other cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRCA2 have source records linked to Glioma susceptibility 1. Association strength is not clinical gene validity.
ERBB2: Receptor tyrosine-protein kinase erbB-2
ERBB2, also called HER2, is a cell-surface receptor tyrosine kinase that works with other ERBB receptors to transmit growth signals. It helps organize signaling and cytoskeletal responses, and abnormal ERBB2 activity is a major feature of several cancers.
2 ClinVar pathogenic / likely pathogenic and 28 uncertain variants in ERBB2 have source records linked to Glioma susceptibility 1. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): IDH1.
ClinVar pathogenic and likely pathogenic variants linked to Glioma susceptibility 1
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PTEN I101T | 101 | Phosphatase tensin-type | Pathogenic / likely pathogenic (★★) |
| PTEN A126V | 126 | Phosphatase tensin-type | Pathogenic / likely pathogenic (★★) |
| PTEN L98R | 98 | Phosphatase tensin-type | Pathogenic / likely pathogenic (★★) |
| PTEN C124S | 124 | Phosphatase tensin-type | Pathogenic / likely pathogenic (★★) |
| PTEN K128E | 128 | Phosphatase tensin-type | Pathogenic / likely pathogenic (★★) |
| TP53 V143M | 143 | DNA binding | Pathogenic / likely pathogenic (★★) |
| TP53 R267W | 267 | DNA binding | Pathogenic / likely pathogenic (★★) |
| TP53 R273L | 273 | DNA binding | Pathogenic / likely pathogenic (★★) |
| TP53 D281V | 281 | DNA binding | Pathogenic / likely pathogenic (★★) |
| TP53 R282P | 282 | DNA binding | Pathogenic / likely pathogenic (★★) |
| ERBB2 E914K | 914 | Protein kinase | Pathogenic / likely pathogenic |
| ERBB2 E939K | 939 | Protein kinase | Pathogenic / likely pathogenic |
Which prediction tools work for Glioma susceptibility 1
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 98 out of 100
- ESM1b (LLR): 98 out of 100
- CATVariant: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 93 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 89 out of 100
- MetaLR: 80 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 69 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Li-Fraumeni syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (188 pathogenic / likely pathogenic).
- Adrenocortical carcinoma, hereditary also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (23 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (6 pathogenic / likely pathogenic).
- Hereditary breast ovarian cancer syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (6 pathogenic / likely pathogenic).
- Hereditary breast cancer also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (5 pathogenic / likely pathogenic).
- PTEN hamartoma tumor syndrome also has ClinVar records linked to PTEN variants; they fall mostly in different places as the Glioma susceptibility 1 variants (147 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to PTEN variants; they fall mostly in different places as the Glioma susceptibility 1 variants (41 pathogenic / likely pathogenic).
- Macrocephaly-autism syndrome also has ClinVar records linked to PTEN variants; they fall mostly in different places as the Glioma susceptibility 1 variants (13 pathogenic / likely pathogenic).
- Familial meningioma also has ClinVar records linked to PTEN variants; they fall mostly in different places as the Glioma susceptibility 1 variants (3 pathogenic / likely pathogenic).
- Urinary bladder cancer also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (6 pathogenic / likely pathogenic).
- Lung adenocarcinoma also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Glioma susceptibility 1 variants (3 pathogenic / likely pathogenic).
Diseases related to Glioma susceptibility 1
- Hereditary breast cancer, also linked to BRCA2, PTEN and TP53
- Ovarian neoplasm, also linked to BRCA2, ERBB2 and TP53
- Prostate cancer, hereditary, also linked to BRCA2, PTEN and TP53
- Ovarian cancer, also linked to BRCA2 and ERBB2
- Hereditary breast ovarian cancer syndrome, also linked to BRCA2 and TP53
- Colorectal cancer, also linked to ERBB2 and TP53
- Gastric cancer, also linked to ERBB2 and TP53
- Urinary bladder cancer, also linked to ERBB2 and TP53
- Lung adenocarcinoma, also linked to ERBB2 and TP53
- Prostate cancer, also linked to BRCA2 and PTEN
- Familial pancreatic carcinoma, also linked to BRCA2 and TP53
- Head and neck squamous cell carcinoma, also linked to PTEN and TP53
Frequently asked questions
Which genes have records linked to Glioma susceptibility 1?
This view contains 4 analyzed proteins: PTEN, TP53, BRCA2, ERBB2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 12 pathogenic or likely pathogenic variants, 52 variants of uncertain significance and 13 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 78 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center